MARC Record from harvard_bibliographic_metadata

LEADER: 01964cam a22003134a 4500
001 013099536-3
005 20120309194529.0
008 110524s2011 flua b 001 0 eng
010 $a 2011022159
020 $a9781439862216 (hardcover : alk. paper)
035 0 $aocn727303322
040 $aDNLM/DLC$cDLC$dDLC
042 $apcc
050 00 $aRC280.T6$bT534 2011
060 10 $aWK 270
082 00 $a616.99/444$223
245 00 $aThyroid cancer :$bfrom emergent biotechnologies to clinical practice guidelines /$ceditors, Angelo Carpi, Jeffrey I. Mechanick.
260 $aBoca Raton :$bTaylor & Francis,$cc2011.
300 $axvii, 390 p. :$bill. ;$c27 cm.
500 $a"A CRC title."
504 $aIncludes bibliographical references and index.
520 $a"Thyroid cancer evaluation and treatment has enjoyed very little evolution in comparison with other disease management strategies. The standard treatment algorithms for thyroid cancer have varied only in response to major, though infrequent, biotechnological innovations. These resultant algorithm node insertions produced paradigm changes, but there has been little to advance the care of the patient with advanced thyroid cancer--until very recently. Perhaps the reasons for a relative lack of interest and scientific progress are the overwhelming likelihood of benignity among thyroid nodules, the overwhelmingly favorable clinical outcome even if a patient has thyroid cancer, and the overwhelming long time required for clinical follow-up of these cancer patients. Unfortunately, the problem now is that we may be overmanaging low-risk patients, and we have not achieved the clinical responses we would have liked with high-risk patients"--Provided by publisher.
650 12 $aThyroid Neoplasms$xtherapy.
650 12 $aThyroid Neoplasms$xdiagnosis.
650 0 $aThyroid gland$xCancer.
700 1 $aCarpi, A.$q(Angelo)
700 1 $aMechanick, Jeffrey I.
988 $a20120215
906 $0OCLC